PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29845251-0	2018	Obovatol inhibits the growth and aggressiveness of tongue squamous cell carcinoma through regulation of the EGF-mediated JAK-STAT signaling pathway.	obovatol	0-8	epidermal growth factor	Homo sapiens	108-111
32122859-6	2020	Treatment with increasing concentration of OB (25-200 muM) significantly lowered the cell proliferation rate as well as considerably reduced the values of various pro-inflammatory cytokines like IL-1beta, TNF-alpha, IL-6.	obovatol	43-45	interleukin 1 alpha	Homo sapiens	195-203
32122859-6	2020	Treatment with increasing concentration of OB (25-200 muM) significantly lowered the cell proliferation rate as well as considerably reduced the values of various pro-inflammatory cytokines like IL-1beta, TNF-alpha, IL-6.	obovatol	43-45	tumor necrosis factor	Homo sapiens	205-214
32122859-6	2020	Treatment with increasing concentration of OB (25-200 muM) significantly lowered the cell proliferation rate as well as considerably reduced the values of various pro-inflammatory cytokines like IL-1beta, TNF-alpha, IL-6.	obovatol	43-45	interleukin 6	Homo sapiens	216-220
31302317-0	2019	Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activation.	obovatol	0-8	NLR family, pyrin domain containing 3	Mus musculus	18-23
31302317-0	2019	Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activation.	obovatol	0-8	absent in melanoma 2	Mus musculus	25-29
31302317-4	2019	STUDY DESIGN/METHODS: Obovatol was treated to macrophages with inflammasome triggers, and secretions of interleukin (IL)-1beta, IL-18, and caspase-1 were measured as readouts of inflammasome activation.	obovatol	22-30	interleukin 1 alpha	Mus musculus	104-126
31302317-4	2019	STUDY DESIGN/METHODS: Obovatol was treated to macrophages with inflammasome triggers, and secretions of interleukin (IL)-1beta, IL-18, and caspase-1 were measured as readouts of inflammasome activation.	obovatol	22-30	interleukin 18	Mus musculus	128-133
31302317-4	2019	STUDY DESIGN/METHODS: Obovatol was treated to macrophages with inflammasome triggers, and secretions of interleukin (IL)-1beta, IL-18, and caspase-1 were measured as readouts of inflammasome activation.	obovatol	22-30	caspase 1	Mus musculus	139-148
31302317-7	2019	RESULTS: Obovatol inhibited NLRP3, AIM2, and non-canonical inflammasomes through inhibition of Asc pyroptosome formation and mitochondrial ROS generation.	obovatol	9-17	NLR family, pyrin domain containing 3	Mus musculus	28-33
31302317-7	2019	RESULTS: Obovatol inhibited NLRP3, AIM2, and non-canonical inflammasomes through inhibition of Asc pyroptosome formation and mitochondrial ROS generation.	obovatol	9-17	absent in melanoma 2	Mus musculus	35-39
31302317-7	2019	RESULTS: Obovatol inhibited NLRP3, AIM2, and non-canonical inflammasomes through inhibition of Asc pyroptosome formation and mitochondrial ROS generation.	obovatol	9-17	steroid sulfatase	Mus musculus	95-98
31302317-9	2019	In mice, obovatol attenuated serum IL-1beta elevation in response to monosodium urate crystals.	obovatol	9-17	interleukin 1 alpha	Mus musculus	35-43
31302317-10	2019	CONCLUSION: Obovatol is suggested as an inhibitor of NLRP3, AIM2, and non-canonical inflammasomes.	obovatol	12-20	NLR family, pyrin domain containing 3	Mus musculus	53-58
31302317-10	2019	CONCLUSION: Obovatol is suggested as an inhibitor of NLRP3, AIM2, and non-canonical inflammasomes.	obovatol	12-20	absent in melanoma 2	Mus musculus	60-64
29845251-7	2018	In addition, obovatol induced apoptosis in SCC9 TSCC cells by increasing caspase 9/3 and apoptotic protease enhancing factor 1 expression levels.	obovatol	13-21	caspase 9	Homo sapiens	73-126
29845251-8	2018	Western blot analysis demonstrated that obovatol inhibited the expression of pro-epidermal growth factor (EGF), Janus kinase (JAK), and signal transducer and activator of transcription (STAT) in SCC9 TSCC cells.	obovatol	40-48	epidermal growth factor	Homo sapiens	77-104
29845251-8	2018	Western blot analysis demonstrated that obovatol inhibited the expression of pro-epidermal growth factor (EGF), Janus kinase (JAK), and signal transducer and activator of transcription (STAT) in SCC9 TSCC cells.	obovatol	40-48	epidermal growth factor	Homo sapiens	106-109
29845251-9	2018	A study of the molecular mechanisms demonstrated that depletion of EGF reversed the obovatol-mediated inhibition of SCC9 TSCC cell growth and aggressiveness.	obovatol	84-92	epidermal growth factor	Homo sapiens	67-70
29845251-11	2018	In conclusion, the results of the present study provided scientific evidence that obovatol inhibited TSCC cell growth and aggressiveness through the EGF-mediated JAK-STAT signaling pathway, suggesting that obovatol may be a potential anti-TSCC agent.	obovatol	82-90	epidermal growth factor	Homo sapiens	149-152
29845251-11	2018	In conclusion, the results of the present study provided scientific evidence that obovatol inhibited TSCC cell growth and aggressiveness through the EGF-mediated JAK-STAT signaling pathway, suggesting that obovatol may be a potential anti-TSCC agent.	obovatol	206-214	epidermal growth factor	Homo sapiens	149-152
27489231-0	2016	Obovatol Induces Apoptosis in Non-small Cell Lung Cancer Cells via C/EBP Homologous Protein Activation.	obovatol	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	67-72
27489231-5	2016	Consistently, obovatol cleaved PARP, activated caspase 9/3 and Bax and attenuated the expression of cyclin D1 in A549 and H460 NSCLCs.	obovatol	14-22	collagen type XI alpha 2 chain	Homo sapiens	31-35
27489231-5	2016	Consistently, obovatol cleaved PARP, activated caspase 9/3 and Bax and attenuated the expression of cyclin D1 in A549 and H460 NSCLCs.	obovatol	14-22	caspase 9	Homo sapiens	47-56
27489231-5	2016	Consistently, obovatol cleaved PARP, activated caspase 9/3 and Bax and attenuated the expression of cyclin D1 in A549 and H460 NSCLCs.	obovatol	14-22	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66
27489231-5	2016	Consistently, obovatol cleaved PARP, activated caspase 9/3 and Bax and attenuated the expression of cyclin D1 in A549 and H460 NSCLCs.	obovatol	14-22	cyclin D1	Homo sapiens	100-109
27489231-6	2016	Interestingly, obovatol upregulated the expression of endoplasmic reticulum stress proteins such as C/EBP homologous protein (CHOP), IRE1alpha, ATF4 and p-elF2 in A549 and H460 NSCLCs.	obovatol	15-23	DNA damage inducible transcript 3	Homo sapiens	100-124
27489231-6	2016	Interestingly, obovatol upregulated the expression of endoplasmic reticulum stress proteins such as C/EBP homologous protein (CHOP), IRE1alpha, ATF4 and p-elF2 in A549 and H460 NSCLCs.	obovatol	15-23	DNA damage inducible transcript 3	Homo sapiens	126-130
27489231-6	2016	Interestingly, obovatol upregulated the expression of endoplasmic reticulum stress proteins such as C/EBP homologous protein (CHOP), IRE1alpha, ATF4 and p-elF2 in A549 and H460 NSCLCs.	obovatol	15-23	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	133-142
27489231-6	2016	Interestingly, obovatol upregulated the expression of endoplasmic reticulum stress proteins such as C/EBP homologous protein (CHOP), IRE1alpha, ATF4 and p-elF2 in A549 and H460 NSCLCs.	obovatol	15-23	activating transcription factor 4	Homo sapiens	144-148
27489231-6	2016	Interestingly, obovatol upregulated the expression of endoplasmic reticulum stress proteins such as C/EBP homologous protein (CHOP), IRE1alpha, ATF4 and p-elF2 in A549 and H460 NSCLCs.	obovatol	15-23	E74 like ETS transcription factor 2	Homo sapiens	155-159
27489231-7	2016	Conversely, depletion of CHOP blocked the apoptotic activity of obovatol to increase sub-G1 accumulation in A549 and H460 NSCLCs.	obovatol	64-72	DNA damage inducible transcript 3	Homo sapiens	25-29
27489231-8	2016	Overall, our findings support scientific evidences that obovatol induces apoptosis via CHOP activation in A549 and H460 NSCLCs.	obovatol	56-64	DNA damage inducible transcript 3	Homo sapiens	87-91
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	obovatol	31-39	B cell leukemia/lymphoma 2	Mus musculus	230-235
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	obovatol	31-39	BH3 interacting domain death agonist	Mus musculus	240-243
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	obovatol	31-39	mitogen-activated protein kinase 14	Mus musculus	369-372
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	obovatol	31-39	jun proto-oncogene	Mus musculus	426-431
20022323-3	2010	METHODS AND RESULTS: Obovatol (1-5 microM) exerted concentration-dependent inhibition on platelet-derived growth factor (PDGF)-BB-induced rat VSMC proliferation, without exhibiting any cellular toxicity or apoptosis, as determined by cell count, [3H]thymidine incorporation and Annexin-V-binding analyses.	obovatol	21-29	annexin A5	Rattus norvegicus	278-287
23446989-7	2013	In these experiments, obovatol strongly inhibited CYP2C19-mediated S-mephenytoin hydroxylase activity with an IC(50) value of 0.8 microM, which could have implications for drug-drug interactions.	obovatol	22-30	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	50-57
23263814-0	2012	Anti-platelet activity of diacetylated obovatol through regulating cyclooxygenase and lipoxygenase activities.	obovatol	39-47	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	86-98
23263814-8	2012	The results demonstrated that diacetylated obovatol has antiplatelet activities through inhibition of COX-1 and LOX activities.	obovatol	43-51	cytochrome c oxidase subunit I	Oryctolagus cuniculus	102-107
23263814-8	2012	The results demonstrated that diacetylated obovatol has antiplatelet activities through inhibition of COX-1 and LOX activities.	obovatol	43-51	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	112-115
22189915-9	2012	In particular, based on the affinity purification approach, peroxiredoxin 2 was identified as a microglial target of obovatol.	obovatol	117-125	peroxiredoxin 2	Homo sapiens	60-75
23132562-0	2012	JJK694, a synthesized obovatol derivative, inhibits platelet activation by suppressing cyclooxygenase and lipoxygenase activities.	obovatol	22-30	polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus	106-118
21512279-11	2011	The antiplatelet activity of obovatol is mediated by inhibition of PLC-gamma2 phosphorylation.	obovatol	29-37	phospholipase C, gamma 2	Rattus norvegicus	67-77
20868677-0	2010	Neurotrophic activity of obovatol on the cultured embryonic rat neuronal cells by increase of neurotrophin release through activation of ERK pathway.	obovatol	25-33	Eph receptor B1	Rattus norvegicus	137-140
20868677-6	2010	We also found that obovatol increased levels of NGF and BDNF released into the culture medium.	obovatol	19-27	nerve growth factor	Rattus norvegicus	48-51
20868677-6	2010	We also found that obovatol increased levels of NGF and BDNF released into the culture medium.	obovatol	19-27	brain-derived neurotrophic factor	Rattus norvegicus	56-60
20868677-7	2010	In addition, the combination of low concentrations of obovatol (1 and 2 muM) with NGF (50 ng/ml) or with BDNF (10 ng/ml) greatly enhanced neurite outgrowth.	obovatol	54-62	nerve growth factor	Rattus norvegicus	82-85
20868677-8	2010	Subsequently, we found that obovatol increased phosphorylation of ERK.	obovatol	28-36	Eph receptor B1	Rattus norvegicus	66-69
20868677-9	2010	However, the neurite outgrowth, and NGF and BDNF release induced by obovatol were prevented by an ERK-specific inhibitor.	obovatol	68-76	nerve growth factor	Rattus norvegicus	36-39
20868677-9	2010	However, the neurite outgrowth, and NGF and BDNF release induced by obovatol were prevented by an ERK-specific inhibitor.	obovatol	68-76	brain-derived neurotrophic factor	Rattus norvegicus	44-48
20868677-9	2010	However, the neurite outgrowth, and NGF and BDNF release induced by obovatol were prevented by an ERK-specific inhibitor.	obovatol	68-76	Eph receptor B1	Rattus norvegicus	98-101
20868677-10	2010	These results suggest that obovatol promotes neurite outgrowth due to the increased release of neurotrophic factors via activation of the ERK pathway.	obovatol	27-35	Eph receptor B1	Rattus norvegicus	138-141
22212065-10	2012	In conclusion, our data demonstrated that obovatol prevented memory impairments in experimental AD models, which could be attributable to amelioration of neuroinflammation and amyloidogenesis by inhibition of NF-kappaB signaling pathway and anti-fibrillogenic activity of obovatol.	obovatol	42-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	209-218
22107706-0	2012	Obovatol attenuates LPS-induced memory impairments in mice via inhibition of NF-kappaB signaling pathway.	obovatol	0-8	toll-like receptor 4	Mus musculus	20-23
22107706-5	2012	We found that obovatol dose-dependently attenuates LPS-induced memory deficit in the Morris water maze and passive avoidance tasks.	obovatol	14-22	toll-like receptor 4	Mus musculus	51-54
22107706-8	2012	Furthermore, LPS-induced nuclear factor (NF)-kappaB DNA binding activity was drastically abolished by obovatol as shown by the electrophoretic mobility shift assay.	obovatol	102-110	toll-like receptor 4	Mus musculus	13-16
22107706-10	2012	These results show that obovatol mitigates LPS-induced amyloidogenesis and memory impairment via inhibiting NF-kappaB signal pathway, suggesting that the compound might be plausible therapeutic intervention for neuroinflammation-related diseases such as AD.	obovatol	24-32	toll-like receptor 4	Mus musculus	43-46
21811927-4	2011	The goal of this study was to examine the cardioprotective effects of the obovatol derivative OD 78 on the TNF-alpha-induced proliferation and migration of rat aortic smooth muscle cells (RASMCs).	obovatol	74-82	tumor necrosis factor	Rattus norvegicus	107-116
18762427-6	2008	In addition, DNA flow cytometric analysis shows that obovatol progresses to apoptosis as detected by flow cytometry after double staining with annexin V and propidium iodide.	obovatol	53-61	annexin A5	Homo sapiens	143-152
20397299-6	2010	Obovatol also inhibited microglial expression of proinflammatory cytokines and inducible nitric-oxide synthase, which was accompanied by the inhibition of multiple signalling pathways such as nuclear factor kappa B, signal transducers and activators of transcription 1, and mitogen-activated protein kinases.	obovatol	0-8	nitric oxide synthase 2, inducible	Mus musculus	79-110
20397299-8	2010	One molecular target of obovatol in microglia was peroxiredoxin 2 (Prx2), identified by affinity chromatography and mass spectrometry.	obovatol	24-32	peroxiredoxin 2	Mus musculus	50-65
20397299-8	2010	One molecular target of obovatol in microglia was peroxiredoxin 2 (Prx2), identified by affinity chromatography and mass spectrometry.	obovatol	24-32	peroxiredoxin 2	Mus musculus	67-71
20397299-9	2010	Obovatol enhanced the reactive oxygen species (ROS)-scavenging activity of Prx2 in vitro, thereby suppressing proinflammatory signalling pathways of microglia where ROS plays an important role.	obovatol	0-8	peroxiredoxin 2	Mus musculus	75-79
19834284-0	2009	Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB.	obovatol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	97-132
19834284-2	2009	Previously, we found that obovatol, an active compound isolated from Magnolia obovata, inhibited cancer cell growth through inhibition of NF-kappaB activity.	obovatol	26-34	nuclear factor kappa B subunit 1	Homo sapiens	138-147
19834284-3	2009	We investigated here whether obovatol could sensitize cancer cells against docetaxel through inhibition of NF-kappaB activity in prostate cancer (LNCaP and PC-3) and colon cancer (SW620 and HCT116) cells.	obovatol	29-37	nuclear factor kappa B subunit 1	Homo sapiens	107-116
19834284-6	2009	Similar combination effects of obovatol with other chemotherapeutic agents (paclitaxel, cisplatin, and doxorubicin) on the inhibition of cell growth and NF-kappaB activity were also found.	obovatol	31-39	nuclear factor kappa B subunit 1	Homo sapiens	153-162
19834284-7	2009	These results indicate that obovatol augments cell growth inhibition by chemotherapeutics through inactivation of NF-kappaB and suggest that obovatol may have therapeutic advantages in the combination treatment with other chemotherapeutics.	obovatol	28-36	nuclear factor kappa B subunit 1	Homo sapiens	114-123
18241858-0	2008	Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB.	obovatol	29-37	nuclear factor kappa B subunit 1	Homo sapiens	124-133
18241858-2	2008	Previously in cultured macrophage Raw264.7 cells and fibroblast, we found that obovatol, an active compound isolated from M. obovata inhibited NF-kappaB activity which has been known to be a significant transcriptional factor to control of cancer cell growth.	obovatol	79-87	nuclear factor kappa B subunit 1	Homo sapiens	143-152
18241858-3	2008	We investigated here whether obovatol could inhibit NF-kappaB activity, and thereby inhibit cancer cell growth in prostate (LNCaP and PC-3) and colon cancer (SW620 and HCT116) cells.	obovatol	29-37	nuclear factor kappa B subunit 1	Homo sapiens	52-61
17346934-0	2007	Increase of collagen synthesis by obovatol through stimulation of the TGF-beta signaling and inhibition of matrix metalloproteinase in UVB-irradiated human fibroblast.	obovatol	34-42	transforming growth factor beta 1	Homo sapiens	70-78
17346934-6	2007	OBJECTIVE: We have investigated increasing effects of obovatol, a biphenolic compound isolated from leaves of Magnolia obovata on the collagen synthesis through stimulation of the TGF-beta signaling and inhibition of matrix metalloproteinase, thereby protect against from UV damages via maintain of collagen in the UVB irradiated human fibroblast cells.	obovatol	54-62	transforming growth factor beta 1	Homo sapiens	180-188
17346934-12	2007	RESULTS: The results showed that obovatol stimulated type I procollagen, TGF-beta, and Smad expression and inhibited matrix metalloproteinase-3 (MMP-3) in dose-dependent manner (1-5muM) in UVB-irradiated human fibroblast cells.	obovatol	33-41	collagen type I alpha 2 chain	Homo sapiens	53-71
17346934-12	2007	RESULTS: The results showed that obovatol stimulated type I procollagen, TGF-beta, and Smad expression and inhibited matrix metalloproteinase-3 (MMP-3) in dose-dependent manner (1-5muM) in UVB-irradiated human fibroblast cells.	obovatol	33-41	transforming growth factor beta 1	Homo sapiens	73-81
17346934-12	2007	RESULTS: The results showed that obovatol stimulated type I procollagen, TGF-beta, and Smad expression and inhibited matrix metalloproteinase-3 (MMP-3) in dose-dependent manner (1-5muM) in UVB-irradiated human fibroblast cells.	obovatol	33-41	matrix metallopeptidase 3	Homo sapiens	117-143
17346934-12	2007	RESULTS: The results showed that obovatol stimulated type I procollagen, TGF-beta, and Smad expression and inhibited matrix metalloproteinase-3 (MMP-3) in dose-dependent manner (1-5muM) in UVB-irradiated human fibroblast cells.	obovatol	33-41	matrix metallopeptidase 3	Homo sapiens	145-150
17346934-14	2007	CONCLUSION: These results suggest that obovatol increases collagen synthesis through stimulation of the TGF-beta signaling and inhibition of matrix metalloproteinase in UVB-irradiated human fibroblast, thus obovatol could be effective against photo-damaged skin.	obovatol	39-47	transforming growth factor beta 1	Homo sapiens	104-112